SPRIM PRO and ObvioHealth, sister companies within the SPRIM Group, have expanded their collaboration to deliver a fully integrated clinical trial solution that combines deep scientific and operational expertise with advanced digital capabilities. This strategic alliance provides trial sponsors with a single, streamlined offering to design and execute more efficient, participant-centric research globally.
Complementary Expertise Drives Innovation
SPRIM PRO brings over 24 years of clinical and operational experience, having supported more than 300 trials across 26 therapeutic areas. The company's core strengths lie in optimizing protocol design, developing validated digital endpoints, and ensuring compliance through comprehensive training and telehealth programs. ObvioHealth complements this foundation with its proprietary ObvioGo platform—an enterprise-grade solution for decentralized and hybrid trials that enables real-time data capture, mobile-first engagement, and flexible digital workflows.
From the earliest stages of trial planning, the two teams collaborate to help sponsors align study design, technology, and engagement strategies. SPRIM PRO advises on endpoint selection and operational strategy, while ObvioHealth ensures that digital usability and operational feasibility are embedded early—minimizing downstream changes and accelerating study startup.
"SPRIM PRO is excited about our partnership with ObvioHealth," said Susan Dallabrida, PhD, CEO at SPRIM PRO. "As CRO and technology partners, we share a commitment to scientific rigor, operational excellence, and data integrity. We also recognize the vital role of innovation in meeting the evolving demands of today's decentralized trials. Participants and sites expect more flexibility and better digital experiences—ObvioGo delivers on both, enabling seamless engagement and communication throughout the trial journey."
Advanced Digital Endpoints and Data Integration
A core strength of the collaboration involves enabling next-generation digital endpoints. SPRIM PRO's track record includes the development and validation of over 300 custom instruments—many leveraging images, audio, and video submitted by participants or caregivers. These endpoints are designed for sensitivity and specificity and are captured seamlessly through the ObvioGo platform, which also integrates wearables, biosensors, and telehealth visits for a more comprehensive data view.
"This partnership with SPRIM PRO allows us to bring science and technology into alignment from day one," said Ivan Jarry, CEO of ObvioHealth. "We've built ObvioGo to remove friction at every stage of the clinical trial journey. By integrating digital workflows early and pairing them with SPRIM PRO's scientific depth and operational rigor, we're offering sponsors a seamless, end-to-end solution that accelerates trial success and delivers data that is both meaningful and regulatory-ready."
Enhanced Participant Engagement and Training
Participant engagement and retention are central to the expanded offering. SPRIM PRO has trained over 125,000 participants, caregivers, and consumers—as well as more than 40,000 healthcare professionals—through customized multimedia programs. These efforts are enhanced by ObvioGo's user-friendly interface, automated reminders, and real-time support—reducing participant burden and improving compliance.
Comprehensive Trial Solutions
With this alliance, SPRIM PRO and ObvioHealth deliver a comprehensive solution that spans trial strategy, digital implementation, operational execution, and participant engagement. Whether running a hybrid or fully decentralized trial, sponsors gain access to a unified solution that enhances evidence quality, shortens timelines, and drives innovation.
The partnership positions both companies to address the growing demand for flexible, technology-enabled clinical trials while maintaining the scientific rigor and regulatory compliance essential for successful drug development programs.
